Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Adial Pharmaceuticals Inc's Business Segments
Adial Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
CODM
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- CODM0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| CODM | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- CODM0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| CODM | - | - |
Description of Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc., also known as Adial, is a clinical-stage biopharmaceutical company based in Charlottesville, Virginia. The company focuses on the development of drugs for the treatment of addiction and related disorders, particularly alcohol use disorder (AUD).
Adial Pharmaceuticals is dedicated to transforming the way alcohol use disorder is diagnosed and treated. With a mission to improve the quality of life for individuals suffering from AUD, the company aims to develop innovative therapeutics that will help patients overcome their addiction and prevent relapses.
The core focus of Adial Pharmaceuticals is on the development of a drug called AD04 (also known as ONWARD™) for the treatment of AUD. AD04 is a genetically targeted therapy that acts on the serotonin-3 receptor (5-HT3) pathway in the brain, which is believed to play a crucial role in the development and maintenance of addiction. By modulating this pathway, AD04 aims to reduce the craving for alcohol, significantly improving the chances of successful recovery.
The company has conducted several clinical trials to evaluate the safety and efficacy of AD04. The most notable among these is the landmark Phase 3 clinical trial called the ONWARD study. This double-blind, placebo-controlled trial evaluated the effects of AD04 in patients with moderate to severe AUD.
Adial Pharmaceuticals has a strong and experienced management team with a deep understanding of the pharmaceutical industry and drug development process. The team comprises industry veterans, scientists, and clinicians dedicated to advancing the field of addiction medicine.
In addition to AD04, Adial Pharmaceuticals is actively engaged in research and development to expand its drug pipeline and address other addiction-related disorders. The company is exploring the potential of developing drugs for the treatment of opioid use disorder, cocaine use disorder, and other substance use disorders.
In terms of intellectual property, Adial Pharmaceuticals holds several patents related to the composition and methods of use of AD04. These patents provide the company with exclusive rights to develop, manufacture, and commercialize AD04 in various countries.
Adial Pharmaceuticals also collaborates with academic institutions, research organizations, and pharmaceutical companies to advance its drug development programs. These collaborations help leverage the expertise and resources of various partners, enhancing the company's ability to develop novel and effective therapies for addiction disorders.
From a market perspective, the potential market for AD04 is significant. Alcohol use disorder affects millions of people worldwide, with limited treatment options currently available. If approved, AD04 has the potential to address this unmet medical need and capture a substantial market share.
Overall, Adial Pharmaceuticals is a dedicated biopharmaceutical company focused on developing innovative therapies for the treatment of addiction disorders. With its flagship drug AD04, the company aims to make a significant impact on the lives of individuals suffering from alcohol use disorder and improve overall public health.
Adial Pharmaceuticals is dedicated to transforming the way alcohol use disorder is diagnosed and treated. With a mission to improve the quality of life for individuals suffering from AUD, the company aims to develop innovative therapeutics that will help patients overcome their addiction and prevent relapses.
The core focus of Adial Pharmaceuticals is on the development of a drug called AD04 (also known as ONWARD™) for the treatment of AUD. AD04 is a genetically targeted therapy that acts on the serotonin-3 receptor (5-HT3) pathway in the brain, which is believed to play a crucial role in the development and maintenance of addiction. By modulating this pathway, AD04 aims to reduce the craving for alcohol, significantly improving the chances of successful recovery.
The company has conducted several clinical trials to evaluate the safety and efficacy of AD04. The most notable among these is the landmark Phase 3 clinical trial called the ONWARD study. This double-blind, placebo-controlled trial evaluated the effects of AD04 in patients with moderate to severe AUD.
Adial Pharmaceuticals has a strong and experienced management team with a deep understanding of the pharmaceutical industry and drug development process. The team comprises industry veterans, scientists, and clinicians dedicated to advancing the field of addiction medicine.
In addition to AD04, Adial Pharmaceuticals is actively engaged in research and development to expand its drug pipeline and address other addiction-related disorders. The company is exploring the potential of developing drugs for the treatment of opioid use disorder, cocaine use disorder, and other substance use disorders.
In terms of intellectual property, Adial Pharmaceuticals holds several patents related to the composition and methods of use of AD04. These patents provide the company with exclusive rights to develop, manufacture, and commercialize AD04 in various countries.
Adial Pharmaceuticals also collaborates with academic institutions, research organizations, and pharmaceutical companies to advance its drug development programs. These collaborations help leverage the expertise and resources of various partners, enhancing the company's ability to develop novel and effective therapies for addiction disorders.
From a market perspective, the potential market for AD04 is significant. Alcohol use disorder affects millions of people worldwide, with limited treatment options currently available. If approved, AD04 has the potential to address this unmet medical need and capture a substantial market share.
Overall, Adial Pharmaceuticals is a dedicated biopharmaceutical company focused on developing innovative therapies for the treatment of addiction disorders. With its flagship drug AD04, the company aims to make a significant impact on the lives of individuals suffering from alcohol use disorder and improve overall public health.
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for treating addiction and related disorders. The company is primarily engaged in creating pharmacological solutions aimed at addressing the growing challenges of substance use disorders, particularly alcohol and opioid use.
Segments
1. Addiction Treatment: This segment is central to Adials operations, focusing on the development of medications that assist individuals struggling with addiction. Given the increasing rates of substance abuse, Adials efforts are particularly relevant in addressing public health issues associated with addiction.
2. Clinical Development: Adial is involved in various stages of clinical trials for its products, advancing them through phases of research to assess safety, efficacy, and dosage. This segment encompasses preclinical studies followed by Phase 1, Phase 2, and Phase 3 trials, as necessary.
3. Regulatory Affairs: This segment pertains to navigating the complex landscape of drug approval processes. Adial engages with regulatory bodies like the FDA to ensure compliance with all necessary regulations, facilitating the approval of its products for marketing.
Products
1. AD04: Adials flagship product, AD04, is an investigational medication designed to treat alcohol use disorder (AUD). It is a targeted medication aimed at reducing the cravings for alcohol and decreasing the likelihood of relapse in individuals recovering from AUD. AD04 has demonstrated promise in clinical trials and aims to provide a non-addictive option in what is typically a market with limited pharmacological solutions.
2. Additional Products in Development: Beyond AD04, Adial is engaged in research for other compounds that target various forms of addiction and behaviors associated with substance use. The specifics of these compounds may involve novel mechanisms of action intended to modulate neurochemical pathways involved in addiction.
Services
1. Clinical Research Services: Adial offers services connected to the conduct of clinical trials, including study design, monitoring, and data analysis. Collaborating with clinical research organizations (CROs) helps them efficiently manage the trials necessary to gather critical data for regulatory submissions.
2. Consultation on Regulatory Strategy: The company provides insights and strategic advice regarding regulatory requirements and pathways to approval. This service is designed to facilitate the process for partners and stakeholders involved in clinical development.
3. Partnership and Licensing Opportunities: Adial seeks partnerships with pharmaceutical companies and academic institutions to enhance its research capabilities. Licensing arrangements may also be a component of its strategy, allowing for wider distribution and commercialization of its products once approved.
Conclusion
Adial Pharmaceuticals Inc. is positioned to play a significant role in the pharmaceutical landscape regarding addiction treatments. Their focused segments, product development, and supportive services reflect a comprehensive approach to addressing substance use disorders. As they progress through regulatory and clinical milestones, their offerings may evolve, capturing a broader spectrum of treatment options for various addiction-related issues.
Segments
1. Addiction Treatment: This segment is central to Adials operations, focusing on the development of medications that assist individuals struggling with addiction. Given the increasing rates of substance abuse, Adials efforts are particularly relevant in addressing public health issues associated with addiction.
2. Clinical Development: Adial is involved in various stages of clinical trials for its products, advancing them through phases of research to assess safety, efficacy, and dosage. This segment encompasses preclinical studies followed by Phase 1, Phase 2, and Phase 3 trials, as necessary.
3. Regulatory Affairs: This segment pertains to navigating the complex landscape of drug approval processes. Adial engages with regulatory bodies like the FDA to ensure compliance with all necessary regulations, facilitating the approval of its products for marketing.
Products
1. AD04: Adials flagship product, AD04, is an investigational medication designed to treat alcohol use disorder (AUD). It is a targeted medication aimed at reducing the cravings for alcohol and decreasing the likelihood of relapse in individuals recovering from AUD. AD04 has demonstrated promise in clinical trials and aims to provide a non-addictive option in what is typically a market with limited pharmacological solutions.
2. Additional Products in Development: Beyond AD04, Adial is engaged in research for other compounds that target various forms of addiction and behaviors associated with substance use. The specifics of these compounds may involve novel mechanisms of action intended to modulate neurochemical pathways involved in addiction.
Services
1. Clinical Research Services: Adial offers services connected to the conduct of clinical trials, including study design, monitoring, and data analysis. Collaborating with clinical research organizations (CROs) helps them efficiently manage the trials necessary to gather critical data for regulatory submissions.
2. Consultation on Regulatory Strategy: The company provides insights and strategic advice regarding regulatory requirements and pathways to approval. This service is designed to facilitate the process for partners and stakeholders involved in clinical development.
3. Partnership and Licensing Opportunities: Adial seeks partnerships with pharmaceutical companies and academic institutions to enhance its research capabilities. Licensing arrangements may also be a component of its strategy, allowing for wider distribution and commercialization of its products once approved.
Conclusion
Adial Pharmaceuticals Inc. is positioned to play a significant role in the pharmaceutical landscape regarding addiction treatments. Their focused segments, product development, and supportive services reflect a comprehensive approach to addressing substance use disorders. As they progress through regulatory and clinical milestones, their offerings may evolve, capturing a broader spectrum of treatment options for various addiction-related issues.